Azithromycin prophylaxis and treatment of murine toxoplasmosis

Khalid F. Tabbara, Ehab Hammouda, Abdulkader Tawfik, Othman M. Al-Omar, Ahmed M. Abu El-Asrar

Research output: Contribution to journalArticle

Abstract

Objective: To evaluate the azithromycin effects alone and in combination with other agents in the prophylaxis and treatment of murine toxoplasmosis. Methods: A total of 280 BALB/c mice were included, and 2 × 103 Toxoplasma organisms of the RH strain Toxoplasma gondii strain ATCC50174 were given intraperitoneally to each mouse. In experiment one, 40 animals were given azithromycin 200 milligram/kilogram/daily for 3 days starting the day of inoculation, 40 mice were control. In experiment 2, the treatment was started 48 hours after inoculation and given daily for 3 days: one group received azithromycin 200 milligram/kilogram/day, the second group received pynmethamine 25 milligram/kilogram/day, and the sulfadiazine 100 milligram/kilogram/day. The third group was control. In experiment 3, 7 groups of animals received one of the following (1) none, (2) azithromycin 200 milligram/kilogram/day, (3) pyrimethamine 25 milligram/kilogram/day and sulfadiazine 100 milligram/kilogram/day, (4) azithromycin and sulfadiazine, (5) azithromycin and pyrimethamine, (6) azithromycin with sulfadiazine and pyrimethamine, (7) sulfadiazine alone. Treatment was initiated 72 hours after inoculation for 3 days. The study was conducted at the Animal Care Facility of King Saud University, Riyadh, Kingdom of Saudi Arabia. Results: Animals that received azithromycin simultaneously with inoculation survived, and all control animals died. All animals died in groups receiving single drug therapy. Animals treated with azithromycin and sulfadiazine showed a survival rate of 40%, sulfadiazine and pyrimethamine 40%, or azithromycin with sulfadiazine and pyrimethamine 95% (p

Original languageEnglish (US)
Pages (from-to)393-397
Number of pages5
JournalSaudi Medical Journal
Volume26
Issue number3
StatePublished - Mar 2005
Externally publishedYes

Fingerprint

Azithromycin
Toxoplasmosis
Sulfadiazine
Pyrimethamine
Therapeutics
Toxoplasma
Saudi Arabia
Drug Therapy
Control Groups

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tabbara, K. F., Hammouda, E., Tawfik, A., Al-Omar, O. M., & Abu El-Asrar, A. M. (2005). Azithromycin prophylaxis and treatment of murine toxoplasmosis. Saudi Medical Journal, 26(3), 393-397.

Azithromycin prophylaxis and treatment of murine toxoplasmosis. / Tabbara, Khalid F.; Hammouda, Ehab; Tawfik, Abdulkader; Al-Omar, Othman M.; Abu El-Asrar, Ahmed M.

In: Saudi Medical Journal, Vol. 26, No. 3, 03.2005, p. 393-397.

Research output: Contribution to journalArticle

Tabbara, KF, Hammouda, E, Tawfik, A, Al-Omar, OM & Abu El-Asrar, AM 2005, 'Azithromycin prophylaxis and treatment of murine toxoplasmosis', Saudi Medical Journal, vol. 26, no. 3, pp. 393-397.
Tabbara KF, Hammouda E, Tawfik A, Al-Omar OM, Abu El-Asrar AM. Azithromycin prophylaxis and treatment of murine toxoplasmosis. Saudi Medical Journal. 2005 Mar;26(3):393-397.
Tabbara, Khalid F. ; Hammouda, Ehab ; Tawfik, Abdulkader ; Al-Omar, Othman M. ; Abu El-Asrar, Ahmed M. / Azithromycin prophylaxis and treatment of murine toxoplasmosis. In: Saudi Medical Journal. 2005 ; Vol. 26, No. 3. pp. 393-397.
@article{3d7dc103b3d64b95bceb841c4367ee70,
title = "Azithromycin prophylaxis and treatment of murine toxoplasmosis",
abstract = "Objective: To evaluate the azithromycin effects alone and in combination with other agents in the prophylaxis and treatment of murine toxoplasmosis. Methods: A total of 280 BALB/c mice were included, and 2 × 103 Toxoplasma organisms of the RH strain Toxoplasma gondii strain ATCC50174 were given intraperitoneally to each mouse. In experiment one, 40 animals were given azithromycin 200 milligram/kilogram/daily for 3 days starting the day of inoculation, 40 mice were control. In experiment 2, the treatment was started 48 hours after inoculation and given daily for 3 days: one group received azithromycin 200 milligram/kilogram/day, the second group received pynmethamine 25 milligram/kilogram/day, and the sulfadiazine 100 milligram/kilogram/day. The third group was control. In experiment 3, 7 groups of animals received one of the following (1) none, (2) azithromycin 200 milligram/kilogram/day, (3) pyrimethamine 25 milligram/kilogram/day and sulfadiazine 100 milligram/kilogram/day, (4) azithromycin and sulfadiazine, (5) azithromycin and pyrimethamine, (6) azithromycin with sulfadiazine and pyrimethamine, (7) sulfadiazine alone. Treatment was initiated 72 hours after inoculation for 3 days. The study was conducted at the Animal Care Facility of King Saud University, Riyadh, Kingdom of Saudi Arabia. Results: Animals that received azithromycin simultaneously with inoculation survived, and all control animals died. All animals died in groups receiving single drug therapy. Animals treated with azithromycin and sulfadiazine showed a survival rate of 40{\%}, sulfadiazine and pyrimethamine 40{\%}, or azithromycin with sulfadiazine and pyrimethamine 95{\%} (p",
author = "Tabbara, {Khalid F.} and Ehab Hammouda and Abdulkader Tawfik and Al-Omar, {Othman M.} and {Abu El-Asrar}, {Ahmed M.}",
year = "2005",
month = "3",
language = "English (US)",
volume = "26",
pages = "393--397",
journal = "Saudi Medical Journal",
issn = "0379-5284",
publisher = "Saudi Arabian Armed Forces Hospital",
number = "3",

}

TY - JOUR

T1 - Azithromycin prophylaxis and treatment of murine toxoplasmosis

AU - Tabbara, Khalid F.

AU - Hammouda, Ehab

AU - Tawfik, Abdulkader

AU - Al-Omar, Othman M.

AU - Abu El-Asrar, Ahmed M.

PY - 2005/3

Y1 - 2005/3

N2 - Objective: To evaluate the azithromycin effects alone and in combination with other agents in the prophylaxis and treatment of murine toxoplasmosis. Methods: A total of 280 BALB/c mice were included, and 2 × 103 Toxoplasma organisms of the RH strain Toxoplasma gondii strain ATCC50174 were given intraperitoneally to each mouse. In experiment one, 40 animals were given azithromycin 200 milligram/kilogram/daily for 3 days starting the day of inoculation, 40 mice were control. In experiment 2, the treatment was started 48 hours after inoculation and given daily for 3 days: one group received azithromycin 200 milligram/kilogram/day, the second group received pynmethamine 25 milligram/kilogram/day, and the sulfadiazine 100 milligram/kilogram/day. The third group was control. In experiment 3, 7 groups of animals received one of the following (1) none, (2) azithromycin 200 milligram/kilogram/day, (3) pyrimethamine 25 milligram/kilogram/day and sulfadiazine 100 milligram/kilogram/day, (4) azithromycin and sulfadiazine, (5) azithromycin and pyrimethamine, (6) azithromycin with sulfadiazine and pyrimethamine, (7) sulfadiazine alone. Treatment was initiated 72 hours after inoculation for 3 days. The study was conducted at the Animal Care Facility of King Saud University, Riyadh, Kingdom of Saudi Arabia. Results: Animals that received azithromycin simultaneously with inoculation survived, and all control animals died. All animals died in groups receiving single drug therapy. Animals treated with azithromycin and sulfadiazine showed a survival rate of 40%, sulfadiazine and pyrimethamine 40%, or azithromycin with sulfadiazine and pyrimethamine 95% (p

AB - Objective: To evaluate the azithromycin effects alone and in combination with other agents in the prophylaxis and treatment of murine toxoplasmosis. Methods: A total of 280 BALB/c mice were included, and 2 × 103 Toxoplasma organisms of the RH strain Toxoplasma gondii strain ATCC50174 were given intraperitoneally to each mouse. In experiment one, 40 animals were given azithromycin 200 milligram/kilogram/daily for 3 days starting the day of inoculation, 40 mice were control. In experiment 2, the treatment was started 48 hours after inoculation and given daily for 3 days: one group received azithromycin 200 milligram/kilogram/day, the second group received pynmethamine 25 milligram/kilogram/day, and the sulfadiazine 100 milligram/kilogram/day. The third group was control. In experiment 3, 7 groups of animals received one of the following (1) none, (2) azithromycin 200 milligram/kilogram/day, (3) pyrimethamine 25 milligram/kilogram/day and sulfadiazine 100 milligram/kilogram/day, (4) azithromycin and sulfadiazine, (5) azithromycin and pyrimethamine, (6) azithromycin with sulfadiazine and pyrimethamine, (7) sulfadiazine alone. Treatment was initiated 72 hours after inoculation for 3 days. The study was conducted at the Animal Care Facility of King Saud University, Riyadh, Kingdom of Saudi Arabia. Results: Animals that received azithromycin simultaneously with inoculation survived, and all control animals died. All animals died in groups receiving single drug therapy. Animals treated with azithromycin and sulfadiazine showed a survival rate of 40%, sulfadiazine and pyrimethamine 40%, or azithromycin with sulfadiazine and pyrimethamine 95% (p

UR - http://www.scopus.com/inward/record.url?scp=17844378447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17844378447&partnerID=8YFLogxK

M3 - Article

C2 - 15806206

AN - SCOPUS:17844378447

VL - 26

SP - 393

EP - 397

JO - Saudi Medical Journal

JF - Saudi Medical Journal

SN - 0379-5284

IS - 3

ER -